Long-term single antiplatelet therapy for patients with acute coronary syndrome at high-risk for ischemia and bleeding: a precision cohort study - Summary - MDSpire
Advertisement
Long-term single antiplatelet therapy for patients with acute coronary syndrome at high-risk for ischemia and bleeding: a precision cohort study
To evaluate the prognostic impacts of various single antiplatelet therapy (SAPT) protocols in high-risk acute coronary syndrome (ACS) patients transitioning from dual antiplatelet therapy (DAPT) to SAPT after 12 months.
Key Findings:
NACE occurrence was similar between aspirin and clopidogrel cohorts (specific statistics needed).
Clopidogrel cohort had a lower occurrence of MACCE (4.3% vs. 9.2%, P = 0.031) and TVR (1.4% vs. 6.4%, P = 0.006) compared to aspirin cohort.
Cox regression analysis showed MACCE and TVR rates were significantly lower in the clopidogrel cohort.
Interpretation:
Transitioning to clopidogrel as SAPT after 12 months of DAPT in high-risk ACS patients is associated with better outcomes in terms of MACCE and TVR, without an increase in bleeding risks.
Limitations:
Single-center study may limit generalizability and introduce biases.
Exclusion of ticagrelor cohort due to small sample size.
Conclusion:
Clopidogrel is a more effective SAPT option than aspirin for high-risk ACS patients post-PCI, reducing adverse cardiovascular events without raising bleeding complications.
Most U.S. adults with hypertension missed blood pressure targets—including those on treatment—highlighting gaps in initiation and intensification of therapy, new JAMA data show.
The organ you forgot, the cells that age unevenly, the AI that admits ignorance, and the diet advice that sounds wrong but isn't: medicine's next moves are hiding in plain sight.
